Enzyvant is a specialized biotech firm focused on creating innovative regenerative treatments for individuals suffering from rare and severe diseases. Their primary product in development is RVT-802, a groundbreaking tissue-based regenerative therapy designed for congenital athymia, an exceptionally rare and life-threatening pediatric immunodeficiency condition. RVT-802 has received various regulatory designations, including an expedited designation as a Regenerative Medicine Advanced Therapy (RMAT) by the US Food and Drug Administration. Enzyvant operates as a subsidiary of Sumitovant Biopharma, a wholly owned entity of Sumitomo Dainippon Pharma.
Enzyvant
Headquarters
United States of America